Vertigo, benign recurrent, 2

Summary

Vertigo, benign recurrent, 2 (MONDO:0013138) is a disease. A subtype of peripheral vertigo — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	vertigo, benign recurrent, 2
Mondo ID	MONDO:0013138
MeSH	C567749
OMIM	613106
UMLS	C2751289
MedGen	442695
GARD	0024903
Is cancer (heuristic)	no

Also known as: BRV2 · vertigo, benign recurrent, 2

Disease family

This is a subtype of peripheral vertigo. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › inner ear disorder › vestibular disorder › peripheral vertigo › vertigo, benign recurrent, 2

Related subtypes (3): endolymphatic hydrops, benign paroxysmal positional vertigo, vertigo, benign recurrent, 1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.